By Zac Ezzone – Staff writer, Triangle Business Journal

Fujifilm Diosynth Biotechnologies will support manufacturing for a Morrisville-based firm’s multiple sclerosis treatment at the company’s $3 billion facility in Holly Springs.

The company has signed a multi-year manufacturing supply agreement to produce the lead product for TG Therapeutics (Nasdaq: TGTX). The product, Briumvi, was approved by the U.S. Food and Drug Administration in 2022.

Fujifilm Diosynth’s Holly Springs site is scheduled to be operational next year. The company will provide secondary, U.S.-based manufacturing supply for Briumvi. TG currently produces the treatment at Samsung Biologics in South Korea. But as the company looks to further grow the treatment, TG decided to find another manufacturing partnership.

“As we continue to expand our commercialization efforts in MS and think about the future of Briumvi, we believe this is an important next step that will continue to support our growth plans and provide additional security for our drug supply,” TG CEO Michael Weiss said during an earnings call Monday.

The companies did not disclose financial details of the agreement.

TG, which in early 2023 began listing Morrisville as its headquarters, on Monday also reported net product revenue from Briumvi in the third quarter of $83.3 million. The company is projecting net revenue from Briumvi for the year to be $300 million to $305 million, surpassing the company’s original full-year guidance for 2024 of $220 million to $260 million.

For Fujifilm, this is the second time the company has confirmed a client for its Holly Springs facility. Fujifilm Diosynth in late 2023 said that Janssen Supply Group, a division of Johnson & Johnson (NYSE: JNJ), would use a large-scale manufacturing suite at the facility.

Fujifilm Diosynth operates as a contract development and manufacturing organization or CDMO, working with pharma and biotech companies to produce biologics, vaccines and other advanced therapies.

The company in 2021 began building out a $2 billion manufacturing facility in Holly Springs. Fujifilm earlier this year increased the size of its investment to about $3.2 billion, which would bring the total size of the site when fully built out to around 1.3 million square feet. The company expects that about 1,400 employees will work at the site by 2031.

The preceding article originally appeared on November 4, 2024 at the Triangle Business Journal’s website and is made available here for educational purposes only. This constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 106A-117 of the U.S. Copyright Law. Photo above: Fujifilm Diosynth Biotechnologies manufacturing facility in Holly Springs.